Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting
17 October 2016 - 10:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced it will
present four new studies at the American Society of Human Genetics
Annual Meeting being held Oct. 18-22, 2016 in Vancouver, British
Columbia. The research being presented highlights the clinical
utility of Myriad’s myVision® Variant Classification Program and
myRisk Hereditary Cancer gene panel test.
“Precision medicine is dependent on the accuracy of
the information being provided to patients, and Myriad’s myVision
is the most advanced variant classification program available to
determine whether a patient's genetic mutation is benign or
deleterious,” said Johnathan Lancaster, M.D., Ph.D, chief medical
officer, Myriad Genetic Laboratories. “At ASHG, we are excited to
present four new studies, which advance the state of the art of
genetic testing and meet the scientific needs of researchers and
clinicians.”
Below is a list of the featured presentations at
ASHG (#ASHG2016):
Platform Presentations
- Title: PMS2CL-hybrid Alleles Containing PMS2
Sequence and Other PMS2CL-derived Large Rearrangements: The
Importance of Correct Interpretation of Dosage Alteration Analysis
in PMS2.Presenter: Nanda
Singh.Date: Thursday, October 20, 2016: 12:00 p.m.
PT.Platform: 137, Ballroom C.
- Title: NGS Facilitates Identification of
Retrotransposon Insertional Mutations in Hereditary Cancer
Genes.Presenter: Yaping
Qian.Date: Thursday, October 20, 2016: 12:45 p.m.
PT.Platform: 156, Room 115.
Poster Presentations
- Title: Characterization of TP53 Sequencing
Variants Initially Detected in Peripheral Blood Using Next
Generation Sequencing Analysis.Presenter: Debora
Mancini-DiNardo.Date: Wednesday, October 19, 2016:
2:00 – 3:00 p.m. PT.Poster: 781W, Exhibit Hall
B.
- Title: Diagnostic Detection, Characterization
& Classification of Partial Single Exon Deletions in Hereditary
Cancer Genes.Presenter: Benjamin
Roa.Date: Wednesday, October 19, 2016: 2:00 – 3:00
p.m. PT.Poster: 763W, Exhibit Hall B.
For more information about these presentations,
including a complete list of abstracts and presentations, please
visit the ASHG website at http://www.ashg.org/2016meeting/.
About Myriad GeneticsMyriad
Genetics Inc., is a leading personalized medicine company dedicated
to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk,
myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G
Safe Harbor StatementThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to the Company presenting four new studies at
the American Society of Human Genetics Annual Meeting being held
Oct. 18-22, 2016 in Vancouver, British Columbia; and the Company’s
strategic directives under the caption “About Myriad Genetics.”
These “forward-looking statements” are based on management’s
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those described or implied in
the forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our existing molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our
ability to transition from our existing product portfolio to our
new tests, including unexpected costs and delays; risks related to
changes in the governmental or private insurers’ reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of a
healthcare clinic in Germany and Sividon Diagnostic and our planned
acquisition of Assurex Health; risks related to our projections
about our business, results of operations and financial condition;
risks related to the potential market opportunity for our products;
the risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents; risks related to changes in
intellectual property laws covering our molecular diagnostic tests
and pharmaceutical and clinical services and patents or enforcement
in the United States and foreign countries, such as the Supreme
Court decision in the lawsuit brought against us by the Association
for Molecular Pathology et al; risks of new, changing and
competitive technologies and regulations in the United States and
internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual report on Form
10-K for the fiscal year ended June 30, 2016, which has been filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Oct 2023 to Oct 2024